Drug Trial Radar · NCT03230526
Identification of a Biomarker Predictive of Evolution of Parkinson Disease
Last checked: Nov 20, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
31
Actual
Start
Apr 16, 2018
Primary completion
May 6, 2024
Study completion May 6, 2024
Sponsor
- Lead sponsor
- Nantes University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 26, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 67 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase II, Open-labeled, Prospective, Multi-center study of assessing the link between microglial activation and dopaminergic denervation kinetics in the early stage of Parkinson disease, by using the imaging of \[18F\]DPA-714 a new ligand of Translocator Protein-18 kDa (TSPO) by Positron Emission Tomography (PET).
Conditions
- Parkinson Disease
Interventions
[18F]DPA-714 PET scanDrug
One PET scan using \[18F\]DPA-714 is done at M2 between two \[123I\]FP-CIT scan (DaTscan) done at M1 and M23. Neuropsychological assessment is done at M0, M18 and M24
Primary outcomes
What the sponsor says the trial is designed to measure.
- Coefficient of correlation between level of microglial striatal activation and the And the dopaminergic denervation kineticsTime frame: 24 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
CHU de Nantes
Nantes, France
Centre Eugène Marquis
Rennes, France
CHU de Rennes
Rennes, France
CHU de Tours
Tours, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.